San Diego, CA – January 10st, 2018 – Avineuro Pharmaceuticals, Inc. reported today promising results of clinical Phase Ib trials on AVN-101, an orally bioavailable and safe multi-target drug candidate for the treatment of CNS diseases associated with memory loss, cognitive dysfunction, neurodegeneration, depression, and general anxiety.

Patients tolerated AVN-101 well in a wide range of doses: no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-101 for treatment of generalized anxiety disorders later this year.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.


Alena Ivachtchenko, MBA
Director of Business Development
Ph:1(786) 617-4449;